Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus BCG for NMIBC
NCT06441110Phase 3Recruiting
- Sponsor
- Fujian Medical University Union Hospital
- Start
- Jun 2023
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tislelizumab in Non-muscle-invasive bladder cancer (NMIBC), sponsored by Fujian Medical University Union Hospital. Primary endpoint: Relapse-Free Survival at 60 months. Started Jun 2023; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
Non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT06441110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06441110.